Hydrea
Developed to alleviate conditions involving abnormal blood cell growth to address long-term stability and symptom control.
Strengths: 500mg
Where to Check Availability
Medicine details
- Alternative names
Hydroxycarbamide
- Therapeutic class
Antineoplastic Agent
- Pharmacological class
Antimetabolite
- Contraindications
severe bone marrow suppression; hypersensitivity
- Minor side effects
nausea; fatigue; diarrhoea
- Moderate side effects
leukopenia; stomatitis; skin ulceration
- Dosage forms
Capsule, hard
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
BMS
- Onset Time
1–2 weeks
- Duration
long-term
- Storage instructions
Store in a cool, dry place.
- Drug interactions
Didanosine; Stavudine
- Age restrictions
Use in children managed by specialists.
Precautions and warnings
regular blood monitoring required; protect skin from sun exposure; maintain high fluid intake
Serious side effects
bone marrow failure — requires immediate medical attention; secondary malignancy — requires immediate medical attention
Patient summary
Developed to alleviate conditions involving abnormal blood cell growth to address long-term stability and symptom control.
Mechanism of action
It works by inhibiting the enzyme ribonucleotide reductase, which is essential for DNA synthesis, effectively slowing the rapid production of abnormal white blood cells or red cells.
Pregnancy and breastfeeding
Pregnancy: Contraindicated; causes fetal harm. Breastfeeding: Contraindicated; do not breastfeed during treatment.
Hydrea
Developed to alleviate conditions involving abnormal blood cell growth to address long-term stability and symptom control.
Editorial Notes
- Active ingredient(s): Hydroxyurea
- Listed indication(s): Chronic Myeloid Leukaemia, Polycythaemia Vera, Essential Thrombocythaemia, Sickle Cell Anaemia
Available option
- 60 tablets - 500 mg270-500-mg-1166